The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | iFCG proves promising for IGHV-mutated CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results from the ongoing phase II trial (NCT02629809) of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) that have a mutated IGHV status but the absence of del(17p)/mutated TP53. The iFCG regimen with only three cycles of chemotherapy proved to be an effective time-limited regimen. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
